Sangamo BioSciences | SGMO - Fremdkapital





Fremdkapital Veränderung Datum
Alaunos Therapeutics USD 4.47M 5.85M 2022-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Alterity Therapeutics Limited AUD 43.68K 59.53K 2025-12
Amgen USD 51.86B 27M 2026-06
Bayer EUR 31.16B 480M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Cipla INR 3.82B 840.2M 2026-03
Clal Biotechnology ILS 25.96M 18.48M 2023-12
Compugen USD 0 0 2024-12
CSL USD 10.42B 273M 2025-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Grifols EUR 9.95B 722.93M 2025-12
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
J&J USD 37.34B 183M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
Merck USD 51.08B 4.41B 2026-06
Novartis USD 37.49B 42M 2026-06
Omeros USD 403.72M 27.2M 2024-06
Pfizer USD 60.5B 70M 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 14.65B 806M 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Tectonic Therapeutic USD 17K 26K 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12